Press Releases
Site - Investor Relations
POAI Subsidiary Helomics Continues Progress Towards Goal of Developing an AI-Driven Predictive Model of Ovarian Cancer
CancerQuest2020 (CCQ2020) is focused on building an AI-driven model of ovarian cancer that will predict drug response and outcome. Predictive models embody the knowledge from these profiles to create a “computational expert” or a “virtual patient” that can be queried. Predictive models such as these are of high value to Pharmaceutical companies as they can be used to quickly select patients for clinical trials and assess potential new drugs or biomarkers computationally (so called “in silico”) before initiating expensive laboratory experiments. Simply put, our predictive models will save time and money in the search for new targeted therapies.
Using the power of AI, the model draws on data generated from over 150,000 tumor cases obtained from 15+ years of clinical testing on living patient tumors, bringing together multi-omic data, i.e. drug response, genomic (mutations), transcriptomic (gene expression) and tissue-omic (tumor pathology) profiles to predict drug response and outcome.
“Despite some headwinds imposed by the current COVID-19 pandemic, the
“In a true team effort across the company we have made solid progress on our CCQ2020 milestones this quarter; we ramped up our sequencing effort as part of our UPMC-Magee collaboration; initiated further digitization of our histopathology slide collection; renewed our collaboration with Genomics
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s
For more information about
About
Forward-looking Statements
Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) the Company’s inability to consummate the private placement due to the failure of one or more closing conditions set forth in the securities purchase agreement to be satisfied, (ii) risks associated with general economic and market conditions, (iii) risks related to the recent merger with
Contact:
651-389-4800
bmyers@skylinemedical.com
Source: Predictive Oncology Inc.